Treatment for Recurrent Ovarian Cancer—At First Relapse

Table 2

Phase II study results for platinum sensitive recurrent ovarian cancer.

	PTX/CBDCA	GEM/CBDCA	PLD/CBDCA	DTX/CBDCA
Author/group	Rose et al. [2]	du Bois et al. [3]	Power et al. [4]∗	Ushijima et al. [5]
		AGO		WJGOG
Dose (mg/m^2)	135/AUC 5-6	1000/AUC 4	30/AUC 5	70/AUC 5
Number of patients	20	25(16)^∗∗	54	29
Response rate (%)	91	63	46	59
PFS (months)	9	10	10	11
OS (months)	10	18	19.1	NA

PTX: paclitaxel; CBOCA: carboplatin; GEM: gemcitabine.
PLD: pegylated liposomal doxorubicin.
PFS: progression free interval; PS: overall survival.
∗Patients who recur within 6 to 12 months.
∗∗Patients with measurable disease.
NA: not applicable.